| Literature DB >> 36207379 |
Yuna Bi1,2, Wei Quan1, Wei Hao3, Rui Sun4, Liwen Li2, Chunping Jiang2, Lingling Tian2, Lin Liu2, Jie Liu2, Xiaozhong Li5, Tao Li6.
Abstract
A nomogram for assessing the risk of IgA vasculitis nephritis (originally termed Henoch-Schönlein purpura nephritis, HSPN) in IgA vasculitis (originally termed Henoch-Schönlein purpura, HSP) pediatric patients can effectively improve early diagnosis and prognosis of IgA vasculitis nephritis. However, currently, no nomogram is available. 246 IgA vasculitis and 142 IgA vasculitis nephritis Asian pediatric patients confirmed by renal biopsy were enrolled. Univariate and multivariate logistic regressions were performed to identify the independent risk factors and construct a series of predictive models. The receiver operating characteristic curve, calibration plot, decision curve analysis, net reclassification index and integrated discrimination index were used to screen the best model. Stratification analysis was applied to optimize model's clinical utility. An external validation set was introduced to verify the predictive efficiency. The final predictive model was converted to nomogram for visual use. We identified age, duration of rash (Dor), D-dimer and IgG as independent risk factors and constructed four models as follows: AIDD (Age + IgG + Dor + D-dimer), AIDi (Age + IgG + D-dimer), AIDo (Age + IgG + Dor) and ADD (Age + Dor + D-dimer), which achieved the receiver operator characteristic curve (AUROC) of 0.931, 0.920, 0.856 and 0.907, respectively. Finally, AIDi model with an AUROC of 0.956 and 0.897 in internal and external validating sets was proposed as a novel predictive model. In stratification analysis by gender and histological grade, the AUROC of AIDi was 0.949 in female, 0.926 in male, 0.933 in mild histological grades and 0.939 in severe histological grades, respectively. AIDi nomogram is an effective and visual tool for assessing the risk of nephritis in IgA vasculitis Asian pediatric patients, regardless of IgA vasculitis nephritis histological grades and gender.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36207379 PMCID: PMC9547060 DOI: 10.1038/s41598-022-20369-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Characteristics of the pediatric patients with IgA vasculitis and IgA vasculitis nephritis.
| Variables (n = 24) | Training set (n = 138) | Internal validation set (n = 128) | ||||
|---|---|---|---|---|---|---|
| IgA vasculitis (n = 90) | IgA vasculitis nephritis (n = 48) | IgA vasculitis (n = 84) | IgA vasculitis nephritis (n = 44) | |||
| Female, n (%) | 41 (45.6) | 21 (43.8) | 0.981 | 33 (39.3) | 24 (54.5) | 0.144 |
| Male, n (%) | 49 (54.4) | 27 (56.2) | 51 (60.7) | 20 (45.5) | ||
| Age (IQR) (years) | 7.00 (5.25, 9.00) | 10.50 (8.00, 12.00) | 0.0001* | 6.00 (5.00, 7.25) | 9.00 (7.00, 11.25) | 0.0001* |
| Weigh (IQR) (kg) | 26.50 (20.50, 37.00) | 43.00 (31.00, 55.75) | 0.0001* | 23.25 (19.00, 29.00) | 38.50 (29.75, 47.88) | 0.0001* |
| Within a month, n (%) | 66 (73.3) | 20 (41.7) | 0.001* | 70 (83.3) | 30 (68.2) | 0.081 |
| More than a month, n (%) | 24 (26.7) | 28 (58.3) | 14 (16.7) | 14 (31.8) | ||
| WBC (IQR) (109/L) | 10.09 (8.33, 12.61) | 10.71 (7.84, 13.09) | 0.853 | 9.54 (7.56, 12.54) | 11.27 (6.31, 16.47) | 0.299 |
| NEU (IQR) (109/L) | 5.98 (3.76, 8.99) | 6.30 (4.34, 9.35) | 0.495 | 5.69 (4.29, 7.86) | 6.86 (4.15, 10.14) | 0.203 |
| LYM (IQR) (109/L) | 2.94 (2.35, 4.06) | 3.08 (2.41, 3.71) | 0.977 | 2.86 (2.18, 3.72) | 3.04 (2.50, 4.97) | 0.056 |
| MON (IQR) (109/L) | 0.63 (0.43, 0.88) | 0.66 (0.40, 0.82) | 0.818 | 0.60 (0.39, 0.77) | 0.70 (0.44, 0.95) | 0.103 |
| PLT (IQR) (109/L) | 355.0 (287.3, 413.0) | 319.5 (280.3, 343.0) | 0.019* | 347.0 (290.3, 403.5) | 303.0 (247.5, 346.0) | 0.001* |
| RBC (1012/L) | 4.71 (4.42, 5.05) | 4.78 (4.41, 4.98) | 0.907 | 4.78 (4.54, 4.94) | 4.82 (4.56, 5.22) | 0.177 |
| HGB (g/L) | 133.7 ± 12.54 | 136.99 ± 15.89 | 0.188 | 134.0 (128.0, 140.3) | 136.5 (132.0, 144.3) | 0.094 |
| MCV (fL) | 84.10 (81.05, 86.38) | 87.35 (84.25, 89.82) | 0.0001* | 82.85 (80.77, 85.43) | 86.35 (83.38, 89.48) | 0.0001* |
| RDW (fL) | 39.80 (38.00, 41.38) | 41.75 (38.85, 44.85) | 0.001* | 39.13 ± 2.61 | 41.21 ± 4.37 | 0.001* |
| PDW (IQR) (fL) | 10.40 (9.20, 11.70) | 10.40 (9.67, 11.93) | 0.363 | 10.55 (9.70, 12.72) | 10.75 (9.78, 12.75) | 0.505 |
| MPV (fL) | 9.40 (8.65, 10.00) | 9.40 (9.20, 10.20) | 0.099 | 9.40 (8.80, 10.05) | 9.75 (8.80, 10.60 | 0.182 |
| CRP (IQR) (mg/L) | 3.52 (1.30, 10.71) | 0.75 (0.25, 1.38) | 0.0001* | 2.78 (1.07, 8.27) | 0.604 (0.21, 1.38) | 0.0001* |
| D-dimer (IQR) (mg/L) | 1.88 (0.90, 3.55) | 0.32 (0.23, 0.51) | 0.0001* | 1.41 (0.70, 2.52) | 0.36 (0.20, 0.62) | 0.0001* |
| APTT (s) | 33.12 ± 6.56 | 32.33 ± 9.38 | 0.568 | 33.97 ± 5.91 | 32.56 ± 5.52 | 0.193 |
| Fib (g/L) | 3.37 (2.73, 3.90) | 3.24 (2.90, 3.76) | 0.461 | 3.34 (2.94, 3.77) | 3.15 (2.33, 3.76) | 0.243 |
| IgA (IQR) (g/L) | 2.29 (1.79, 2.68) | 2.05 (1.78, 2.16) | 0.166 | 2.22 (1.65, 2.88) | 2.05 (1.62, 2.11) | 0.022* |
| IgM (IQR) (g/L) | 1.15 (0.89, 1.42) | 1.34 (0.84, 1.54) | 0.137 | 1.02 (0.83, 1.35) | 1.50 (1.00, 1.64) | 0.001* |
| IgG (IQR) (g/L) | 10.25 (8.69, 12.38) | 9.30 (6.11, 9.87) | 0.0001* | 10.10 (8.70, 12.35) | 7.64 (5.12, 9.87) | 0.0001* |
| C3 (g/L) | 1.22 ± 0.22 | 1.14 ± 0.13 | 0.033* | 1.21 (1.07, 1.35) | 1.15 (1.08, 1.28) | 0.251 |
| C4 (g/L) | 0.25 (0.21, 0.30) | 0.23 (0.21, 0.26) | 0.071 | 0.24 (0.21, 0.31) | 0.23 (0.20, 0.26) | 0.146 |
| I, n (%) | – | 4 (8.3) | – | – | 5 (11.4) | – |
| IIa, n (%) | – | 11 (22.9) | – | – | 8 (18.1) | – |
| IIb and above, n (%) | – | 33 (68.8) | – | – | 31 (70.5) | – |
*p < 0.05 for significance.
#Means the time of rash recurrent or persistent.
WBC white blood cell, NEU neutrophil, LYM lymphocyte, MON monocyte, PLT platelet, RBC red blood cell, HGB hemoglobin, MCV mean corpuscular volume, RDW red cell distribution width, PDW platelet distribution width, MPV mean platelet volume, CRP c-reaction protein, APTT activated partial thromboplastin time, Fib. fibrinogen, IQR interquartile range.
Univariate and multivariate analysis of risk factors for nephritis in IgA vasculitis in training set.
| Variables | IgA vasculitis vs. IgA vasculitis nephritis in training set | |||||
|---|---|---|---|---|---|---|
| Univariate | Multivariate | |||||
| OR | 95% CI | OR | 95% CI | |||
| Age (years) | 1.477 | (1.275, 1.739) | 0.0001* | 1.297 | (1.036, 1.663) | 0.029* |
| Weight (kg) | 1.069 | (1.041, 1.103) | 0.0001* | – | – | |
| Duration of rash# | 3.850 | (1.855, 8.189) | 0.0001* | 3.606 | (1.127, 1.285) | 0.036* |
| PLT count (109/L) | 0.996 | (0.991, 1.000) | 0.037* | 0.995 | (0.988, 1.002) | 0.184 |
| CRP (mg/L) | 0.701 | (0.558, 0.835) | 0.0001* | 0.889 | (0.703, 1.022) | 0.213 |
| D-dimer (mg/L)§ | 0.028 | (0.007, 0.093) | 0.0001* | 0.063 | (0.010, 0.284) | 0.001* |
| IgG (g/L) | 0.716 | (0.607, 0.829) | 0.0001* | 0.648 | (0.478, 0.828) | 0.002* |
| C3 (g/L) | 0.124 | (0.016, 0.815) | 0.036* | 0.586 | (0.009, 1.285) | 0.795 |
| C4 (g/L) | 0.006 | (0.000, 0.644) | 0.042* | 0.001 | (0.000, 6.352) | 0.157 |
*p < 0.05 for significance.
#Means the time of rash recurrent or persistent.
§The result is the square root of the D-dimer.
PLT platelet, CRP C-reaction protein, CI confidence interval, OR odds ratio.
Figure 1Receiver operating characteristic curve analysis of 4 independent risk factors and 4 combined models for predicting the risk of IgA vasculitis nephritis in training set. AUROC of the age (A), duration of rash (B), D-dimer (C), IgG (D), AIDD (E), AIDi (F), AIDo (G) and ADD (H). *Based on the square root of the D-dimer level.
Figure 2Model calibration and discrimination of 4 combined model for predicting the risk of IgA vasculitis nephritis. Calibration plot (A,B), net reclassification index (C) and decision curve analysis (D,E). IgA vasculitis nephritis.
The predictive efficiency of AIDD and AIDo was evaluated by NRI and IDI in training set.
| Estimate | SE | 95% CI | ||
|---|---|---|---|---|
| NRI | 0.301 | 0.128 | (0.062, 0.569) | 0.018* |
| NRI+ | 0.313 | 0.110 | (0.089, 0.517) | 0.005* |
| NRI− | − 0.011 | 0.043 | (− 0.069, 0.095) | 0.795 |
| IDI | 0.168 | – | (0.107, − 0.230) | 0.0001* |
*p < 0.05 for significance.
NRI net reclassification index, IDI integrated discrimination index, CI confidence interval, SE standard error.
Figure 3AIDi nomogram for predicting the risk of IgA vasculitis nephritis.
Figure 4Receiver operating characteristic curve analysis of AIDi nomogram for predicting the risk of IgA vasculitis nephritis in different stratified sets. AUROC of the AIDi predicting the development of IgA vasculitis nephritis in external validating set (n = 122) (A) and in all validating set (internal and external validation, n = 250) (B); AUROC of AIDi predicting the risk of IgA vasculitis nephritis in the mild histological grades group (I and IIa, n = 35) (C) and the sever histological grades (IIb and above, n = 57) (D); AUROC of the AIDi predicting the risk of IgA vasculitis nephritis in females (n = 119) (E) and males (n = 147) (F).
Figure 5Flow chart of patients’ enrollment, grouping and the study design.